Medpace Holdings, Inc. 4

President & CEO August J. Troendle sold 23,144 shares of Medpace Holdings, Inc. common stock for about $13.9 million over two days at prices around $602–$605 per share.

On August 10 and 11, 2026, Medpace Holdings, Inc. President & CEO August J. Troendle sold a total of 23,144 shares of Medpace common stock pursuant to a limit order during an open trading window, at weighted average prices of $601.53 and $605.11 per share, respectively. The sales, executed in multiple transactions within disclosed price ranges, generated proceeds of approximately $13.9 million. Following these dispositions, Troendle directly owns 615,802 shares of Medpace common stock and also has indirect beneficial ownership of 4,733,019 additional shares held through Medpace Investors, LLC, over which he exercises sole voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Filing Facts

CIK

1668397

Ticker

MEDP

Form

4

Source Type

fda

Accession

0001622058-26-000006

Alert Tier

7